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Parathyroid hormone-related protein secretion is
inhibited by oestradiol and stimulated by antioestrogens
in KPLm3C human breast cancer cells
J Kurebayashi and H Sonoo
Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-01, Japan
Summary We recently established a human breast cancer cell line, KPL-3C, from a breast cancer patient with humoral hypercalcaemia. This
cell line possesses oestrogen receptor (ER) and secretes parathyroid hormone-related protein (PTHrP) into medium. To investigate the
effects of oestrogen and antioestrogens on PTHrP secretion, KPL-3C cells were cultured for 48 h in an oestrogen-eliminated medium with
17,B-oestradiol (E2), tamoxifen (TAM) and/or a pure antioestrogen, IC1182,780 (ICI), and PTHrP secretion was measured using an
immunoradiometric assay. The effects of these agents on cell cycle progression were also studied using flow cytometry. E2 (1-100 nM)
significantly inhibited PTHrP secretion, whereas both TAM (0.1-10 gM) and ICI (1-100 nM) significantly stimulated it. These effects were
completely blocked by the simultaneous addition of 1 nM E2 to the medium. Atthe same time, E2 significantly increased the percentage of cells
during the S and G/M phases, whereas both antioestrogens significantly increased the percentage of cells during the GO/G1 phase. Again,
these cytostatic effects were completely reversed by the addition of E2. These findings indicate that antioestrogens inhibit the growth of ER-
positive breast cancer cells but may stimulate PTHrP secretion and that these effects may be mediated by ER.
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Parathyroid hormone-related protein (PTHrP) was first purified
from culture medium obtained from a human lung cancer cell line,
established from a hypercalcaemic patient, and its complementary
DNA was cloned by the same group (Moseley et al, 1987; Suva et
al, 1987). PTHrP secreted by malignant cells has been proved to
be the main cause of humoral hypercalcaemia associated with
malignancy (Burtis et al, 1990; Grill et al, 1991; Ratcliffe et al,
1992). In this situation, PTHrP acts on kidney and bone as a
circulating hormone like parathyroid hormone and subsequently
induces hypercalcaemia. The PTHrP secreted by cancer cells act
as autocrine and paracrine mediators that stimulate the growth of
cancer cells (Kaiser et al, 1992; Benitez-Verguizas et al, 1994;
Iwamura et al, 1994) and activate osteoclasts to produce osteolytic
metastasis (Southby et al, 1990; Bundred et al, 1991; Powell et al,
1991; Birch et al, 1995). In addition, recent reports suggest that
PTHrP may play a certain role in cancer invasion and metastasis
(Vargas et al, 1992; Li and Drucker, 1994; Luparello et al, 1995;
Akino et al, 1996). These findings support the hypothesis that
PTHrP plays akey role in malignantprogression and that suppres-
sion ofPTHrP production and secretion from malignancy could be
an attractive strategy for cancer therapy.
Regulation of PTHrP secretion has been widely studied in
cancer cell lines (Deftos et al, 1989; Emly et al, 1994; Endo et al,
1994; Merryman et al, 1994; Rizzoli et al, 1994), human T-cell
lymphotrophic virus, type I-infected T cells (Inoue et al, 1993),
normal and transformed keratinocytes (Henderson et al, 1991;
Kremer et al, 1991; Allinson and Drucker, 1992), primary cultures
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of mammary epithelial cells (Thiede, 1989; Ferrari et al, 1992;
Sebag et al, 1994), pituitary cells (Holt et al, 1994) and cultured
amniotic fluid cells (Dvir et al, 1995). Steroid hormones, such as
glucocorticoids, vitamin D and its analogues and progestins are
reported to inhibit PTHrP secretion. On the otherhand, it has been
reported that growth factors, such as epidermal growth factor,
insulin-like growth factors I and II, transforming growth factor
beta (TGF-P) and peptide hormones, such as human calcitonin,
prolactin and placental lactogen, stimulate PTHrP secretion.
However, there are only four reports describing the effect of
oestrogen on PTHrP expression or secretion. Two ofthese suggest
that exogenous administration of 17f-oestradiol (E2) stimulated
PTHrP expression in rat uterus in vivo (Thiede et al, 1991;
Paspaliaris et al, 1992). One of these reports suggests that E2
induced arapid andtransient increase in PTHrP mRNA expression
in rat pituitary cells (Holt et al, 1994); the other suggests that E2
has no effect on PTHrP secretion from cultured amniotic fluid
cells (Dvir etal, 1995). To the best ofourknowledge, no report has
described the effects of oestrogen and antioestrogens on PTHrP
secretion from oestrogen receptor (ER)-positive breast cancer
cells. Because immmunohistochemical, in situ hybridization or
polymerase chain reaction analyses have demonstrated that 60%
of primary breast cancers express PTHrP (Southby et al, 1990;
Bundred et al, 1991; Powell et al, 1991; Birch et al, 1995) and ER
expression is one of the most characteristic features of breast
cancer, it is conceivable that there might be an oestrogenic
regulation of PTHrP production and secretion in breast cancer.
Therefore, the regulation of oestrogen and antioestrogens on
PTHrP secretion was investigated in this study using a human
breast cancer cell line, KPL-3C, which possesses both ER and
progesterone receptor (PgR) and stably secretes immunoreactive
PTHrP into culture medium (Kurebayashi et al, 1996). In addition,
to investigate the relationship between PTHrP secretion and cell
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cycle, the effect of oestrogen and antioestrogens on cell cycle
progression was also analysed in this cell line.
MATERIALS AND METHODS
Chemicals
E2 was purchased from Sigma Chemical (St Louis, MO, USA).
Tamoxifen citrate (TAM) and a pure steroidal antioestrogen,
ICI182,780 (ICI) were kindly provided by Zeneca Pharma-
ceuticals (Macclesfield, UK). A stock solution ofthese chemicals
was prepared in 100% ethanol, with the final concentration of
ethanol being 0.1%. Control cells were treated with the culture
medium supplemented with 0.1% ethanol.
Cell culture
The KPL-3C human breast cancer cell line was recently estab-
lished from the malignant pleural effusion of a breast cancer
patient with humoral hypercalcaemia ofmalignancy. The histolog-
ical type of the primary tumour of this cell line was an invasive
ductal carcinoma. KPL-3C cells were maintained in RPMI-1640
medium supplemented with 5% fetal calf serum. The population
doubling time was approximately 72 h at the exponential growth
phase (Kurebayashi et al, 1996).
For the following experiments, KPL-3C cells were plated at a
density of2 x 105 cells per well in 12-well plates in phenol red-free
RPMI-1640 medium supplemented with 2% dextran-coated char-
coal-stripped fetal calf serum (Scholl et al, 1983) (E2-eliminated
medium). When the cells became semiconfluent, the E2-eliminated
medium supplemented with various concentrations of E2, TAM
and/or ICI was added to the wells after washing twice with phos-
phate-buffered saline (PBS). After 48 h, conditioned medium was
collected and centrifuged at 1500 g for 10min to remove the
contamination of floating cells, and the PTHrP concentration of
the supermatant was measured by an immunoradiometric assay
(IRMA) or aC-terminal-region-specific radioimmunoassay (RIA).
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Figure 1 Effects of E2 and antioestrogens on PTHrP secretion from KPL-3C
cells. After washing with PBS, semiconfluent KPL-3C cells were incubated
with E2-eliminated medium supplemented with various concentrations of
agents for 48 h. Conditioned media were collected, and the concentration of
PTHrP was measured by an IRMA. PTHrP secretion was calculated as
described in Materials and methods. Values represent the mean percentages
of control. Bars show s.d. *P< 0.05 in comparison with control; **P< 0.01 in
comparison with control
The treated cells were trypsinized and harvested to measure the
number of cells by trypan blue exclusion and to analyse the cell
cycle by flow cytometry.
Measurement of PTHrP
The PTHrP concentration in the conditioned media was measured
with a two-site IRMA kit (Mitsubishi Petrochemical, Tokyo,
Japan) as described elsewhere (Ikeda et al, 1994). Briefly, a rabbit
anti-human PTHrP (50-83) polyclonal antibody and a mouse
anti-human PTHrP (1-34) monoclonal antibody were used, with
recombinant human PTHrP (1-87) being used as the standard in
this assay. The detection limit was 0.5 pM, and the coefficients of
intra- and interassay variations were not higher than 7.5%. On the
basis of our previous report (Kurebayashi et al, 1996), the PTHrP
secretion into the medium was defined as follows:
concentration ofPTHrP
x volume ofmedium
Secretion per cell per 48 h =
mean cell number
The basal PTHrP secretion from the control cells was approxi-
mately 8 fmol per /106 cells per 48 h. PTHrP secretion from the
treated cells was expressed as percentages ofthe control.
To investigate the effect ofE2 and antioestrogens on proteolytic
processing of mature PTHrP, C-terminal PTHrP was also
measured by a C-terminal-region-specific RIA kit (Daiichi
Radioisotope Laboratories, Chiba, Japan) as described elsewhere
(Kasahara et al, 1992). Briefly, a sheep antiserum immunized with
a synthetic human PTHrP(109-141) was used, with an '25I-
labelled synthetic peptide, [Tyr'08] PTHrP(108-141), being used as
a tracer in this assay. Neither human PTHrP(1-34) nor human
PTHrP(67-86) has been reported to cross-react in this assay. The
detection limit was 2.0 pM for recombinant human PTHrP-
(109-141), and the coefficients of intra- and interassay variations
were 5.9% and 3.9% respectively.
Cell cycle analysis
To investigate the effects of the agents on cell cycle progression,
KPL-3C cells were trypsinized, harvested and stained with
propidium iodine using the CycleTest Plus DNA Reagent Kit
(Becton Dickinson, San Jose, CA, USA). Flow cytometry was
performed with a FACSort flow cytometer (Becton Dickinson),
and the DNA histogram was analysed by a CellFit Cell-Cycle
system (Becton Dickinson).
Statistical analysis
PTHrP secretion and the percentage of cells in the control group
and treatment group during each cell cycle phase were compared
using the one-way analysis of variance. All of the control and
treatment groups were tested in triplicate, and each experiment
was performed at least twice to confirm its reproducibility.
RESULTS
Regulation of PTHrP secretion by E2 and
antioestrogens
As shown in Figure 1, 1-100 nM E2 significantly inhibited
PTHrP secretion from KPL-3C cells (mean percentage of
British Journal ofCancer (1997) 75(12), 1819-1825 0 CancerResearch Campaign 1997PTHrP secretion in breastcancercells 1821
Table 1 Effects of oestradiol and antioestrogens on cell proliferation and
PTHrP secretion in KPL-3C human breast cancer cellsa
Control 1 nM E2 1 gLM TAM 1 nM ICI
Cell no. (x106) 1.1 ± 0.1 1.1 ± 0.2 0.9+ 0.2 0.9± 0.1
PTHrP concentration (pM) 8.7 ± 0.2 7.4 ± 0.7 10.5 ± 0.3 10.6 ± 0.4
PTHrP secretionb 7.9+0.2 6.7+0.6 11.7 +0.3 11.8 +0.5
Percentage of control 100 ±2 83 ± 7 144 ±4 146 ±6
aSemiconfluent KPL-3C cells were incubated with E2-eliminated medium
supplemented with various concentrations of agents for 48 h. After
incubation, the conditioned medium was collected and the cell number was
counted. The concentration of PTHrP was measured by an IRMA. Values
represent means ± s.d. bPTHrP secretion (femtomoles) per 106 cells per 48 h
was calculated as described in Materials and methods.
control ±s.d.: 82 ±13 for I nM, P < 0.05; 67+ 0 for 10 nM,
P < 0.01; 68 ± 3 for 100 nM, P < 0.01). In contrast, 0.1-10 gM
TAM significantly stimulated PTHrP secretion (138 ± 17 for
0.1 ,UM, 143 ± 3 for 1.0 ,UM and 118 ± 1 for 10 ,UM; P < 0.01 in each
comparison). PTHrP secretion was also significantly stimulated by
1.0-100 nM ICI in a dose-dependent manner (143 ± 0 for 1.0 nM,
157 ± 7 for 10 nm and 205 ± 12 for 100 nM; P < 0.01 in each
comparison).
Representative experimental data on the numberofcells perwell,
PTHrP concentration measured by an IRMA, PTHrP secretion per
106cells per48 h and its percentage ofcontrol are shown inTable 1.
Becausethe semiconfluent KPL-3C cells grew slowly, the effects of
E2 and antioestrogens on the cell proliferation were limited.
E2 blocks the stimulation of PTHrP secretion by
antioestrogens
Simultaneous addition of 1 nM E2 to the medium completely
blocked the stimulative effect of 1.0 ,UM TAM on PTHrP secretion
from KPL-3C cells (Figure 2A). No significant difference in
PTHrP secretion was seen between the E2-treated group and the
E2 plus TAM-treated group (79 ± 9 and 78 ± 10 respectively).
Simultaneous addition of 1 nm E2 also completely blocked the
stimulative effect of 1 nM ICI on PTHrP secretion (Figure 2B),
with no difference in PTHrP secretion again being seen between
the E2-treated group and the E2 plus ICI-treated group (80 ±4 and
80 ± 2 respectively).
Effects of E2 and antioestrogens on cell cycle
As shown in Table 2, 1-100 nm EB2 significantly increased the
percentage of cells during the S and G2IM phases (P < 0.05 or
P < 0.01 in each comparison) and decreased the percentage during
theGJG1 phase (P <0.01 in allcomparisons). Incontrast, 0.1-10 JM
TAM significantly increased thepercentage ofcells during theGJG,
phase and significantly decreased the S-phase fraction (P < 0.01 in
all comparisons) in adose-dependent manner. In addition, 1-100 nM
ICI significantly increased the percentage ofcells during the GIG1
phase and decreased the S-phase fraction in a dose-dependent
manner (P < 0.01 in all comparisons).
E2 reverses the cytostatic effect of antioestrogens
As shown in Table 3, simultaneous addition of 1 nM E2 to the
medium completely reversed the G1-S block by 1 JM TAM. No
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Figure 2 E2 blocked the stimulative effect of antioestrogens on PTHrP
secretion from KPL-3C cells. (A) Simultaneous addition of 1 nM E2 to the
medium blocked the effect of TAM on PTHrP secretion. (B) Simultaneous
addition of E2 blocked the effect of ICI. Values represent the mean
percentages of control ± s.d. **P< 0.01 in comparison with control
difference was seen between the control group and the E2 plus
TAM-treated group in the percentage of cells during each cell
cycle phase. Furthermore, the G1-S block by 1 nMICI was also
reversed by simultaneous addition of 1 nm E2. No difference in the
percentage ofcells was seen between the E2-treated group and the
E2 plus ICI-treated group during each cell cycle phase.
Reproducibility of the experimental results
In the separate experiments, similar findings described above were
reproducibly observed. Among the experiments, the coefficients of
variation of percentage of control of PTHrP secretion and of
percentage of cells during a GIG1 phase after the treatment with
each agent were less than 10%. Forexample, percentages ofcontrol
of PTHrP secretion treated with 1 nM E2 in three separate experi-
ments were 82 ± 13 as shown in Figure 1, 79 ± 9 in Figure 2A and
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Table 2 Effects of oestradiol and antioestrogens on the cell cycle progression of KPL-3C cellsa
Agent Percentage of cells during each cell cycle phase
GIG1 S G2/M
None 59.6 ± 0.3 27.5 ± 0.8 12.8 +0.5
1 nM E2 55.8 ±0.3** 30.2 +0.5** 14.0 ± 0.2**
10 nM E2 55.1 ±0.1** 31.9 ±0.5** 13.1 ±0.4
100 nM E2 57.0 ± 0.3** 29.2 ± 0.5** 13.9 ± 0.2**
0.1 gMTAM 61.1 ±0.5** 24.9± 0.9* 14.1 +0.4**
1 gMTAM 62.7±0.1** 24.6±0.4** 12.8 ±0.3
10gM TAM 67.1 ±0.3** 21.2 ±0.2** 11.7 ±0.1*
1 nMICI 65.4±0.1* 21.2±0.2** 13.4+0.1*
10 nM ICI 67.7 ±0.1* 19.8 ±0.2** 12.5 ± 0.2
100 nM ICI 69.2 ±0.2** 17.6 ±0.3** 13.2 ± 0.2
aSemiconfluent KPL-3C cells were incubated with E2-eliminated medium supplemented with
various concentrations of agents for 48 h. After incubation, the cells were trypsinized, harvested,
stained with propidium iodine and analysed by flow cytometry. Values represent mean
percentages ± s.d. *P< 0.05 in comparison with control; **P < 0.01 in comparison with control.
Table 3 Oestradiol reverses the cytostatic effects of antioestrogens in KPL-3C cellsa
Agent Percentage of cells during each cell cycle phase
GJGI S G/M
None 56.1 ±0.4 31.2 + 0.6 12.8 ± 0.3
1 nm E2 53.6 ±0.2** 34.2 ±0.2** 12.2 +0.4
1 gM TAM 61.6 ±0.1* 27.4 ±0.3** 11.0 +0.2**
E2+TAM 57.2 ± 0.2 30.2 ± 0.8 12.3 ± 0.5
None 58.4± 0.1 27.2 ± 0.2 14.4+ 0.2
1 nM E2 57.6 ± 0.2** 26.8 ± 0.2 15.6 ± 0.2**
1 nM ICI 62.3 ±0.4** 23.0 ±0.4** 14.7 ± 0.3
E2+ICI 57.8 ± 0.4 27.6± 0.5 14.6 ± 0.5
aSemiconfluent KPL-3C cells were incubated with E2-eliminated medium supplemented with the
indicated concentrations of each antioestrogen and/or 1 nm E2 for 48 h. After incubation, the
collected cells were stained with propidium iodine and analysed by flow cytometry. Values
represent mean percentages ± s.d. **P< 0.01 in comparison with control.
80 ± 4 in Figure 2B. In addition, percentages ofcells during G/G,
phase treated with 1 nm E2 in three separate experiments were
55.8 ± 0.3 as shown in Table 1 and 53.6 ± 0.2 and 57.6 ± 0.2 in
Table 2.
0 Correlation between PTHrP concentration measured by
an IRMA and by a C-terminal RIA
As shown in Figure 3, PTHrP concentration measured by an IRMA
was significantly correlated with thatmeasuredby aC-terminal RIA.
The concentration ofC-terminal PTHrP was slightly higher than the
PTHrP concentration measured by an IRMA in each sample. These
findings suggest that the amount ofC-terminal PTHrP may contain
both mature and degraded PTHrP and that the amount of degraded
PTHrP may be small in this culture condition.
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Figure 3 Linear correlation of the concentration of PTHrP measured by an
IRMA with the concentration of C-terminal PTHrP measured by an RIA in
culture medium (the correlation coefficient was 0.98, P < 0.01). Conditioned
media treated with or without oestrogen or antioestrogens for 48 h were
collected, and both PTHrP measurements were performed in each sample as
described in Materials and methods
DISCUSSION
Although PTHrP was originally isolated from malignancies asso-
ciated with humoral hypercalcaemia and proved to be the main
cause of malignancy-associated hypercalcaemia, recent studies
suggest that this protein plays important roles in cell growth and
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differentiation in normal organs (Martinet al, 1991). Expression of
PTHrP has been demonstrated in most primary breast cancers, and
higher expression of PTHrP has been noted in bone metastasis
from breast cancer. It has also been suggested that PTHrP may
play a role in the development ofosteolytic metastasis. In addition,
our previous study suggested that PTHrP might play a role
in the deposition of microcalcifications in breast cancer tissues
(Kurebayashi et al, 1996). Other researchers have suggested
certain roles ofPTHrP as autocrine and paracrine growth factors in
breast cancer cells (Birch et al, 1995). These findings support the
hypothesis that PTHrP may be a key factor inducing malignant
progression of breast cancer and that suppression of its production
and secretion may be effective in the inhibition of breast cancer
growth and in the reduction of cancer-related morbidity, such as
hypercalcaemia and pathological fractures.
The regulation of PTHrP production and secretion has been
widely studied in various cell lines and cell cultures of human
normal cells. Very recently, some human breast cancer cell lines
have been reported to express PTHrP (Tabuenca et al., 1995; Birch
et al, 1996). However, the amount of PTHrP secreted into culture
medium from such cell lines is too small to investigate the effects
of agents on PTHrP secretion (unpublished data). Recently, we
established a novel human breast cancer cell line, KPL-3C, derived
from a patient with humoral hypercalcaemia, and preliminary char-
acterization revealed that this cell line possesses both ER and PgR
and stably secretes a detectable amount of immunoreactive PTHrP
into the culture medium. A glucocorticoid, progestin and vitamin D
analogue significantly inhibited PTHrP secretion from KPL-3C
cells in a dose-dependent manner (Kurebayashi et al, 1996). This
background prompted us to investigate the effects ofoestrogen and
antioestrogens on PTHrP secretion in this cell line.
Unexpectedly, PTHrP secretion from KPL-3C human breast
cancer cells was clearly inhibited by E2 and stimulated by either a
non-steroidal antioestrogen, TAM, or a pure steroidal anti-
oestrogen, ICI. To the best ofour knowledge, this is the first report
demonstrating these interesting phenomena. However, it should be
noted that neither PTHrP mRNA level nor proteolytic processing
of mature PTHrP was investigated in this study. The concentration
of C-terminal PTHrP was linearly correlated with the concentra-
tion measured by an IRMA in culture media (Figure 3). This result
indicates that both production and secretion ofmature PTHrP from
KPL-3C cells may be regulated by oestrogen and antioestrogens
and that alteration of proteolytic processing of mature PTHrP is
unlikely to be a main factor causing this regulation. Further studies
are needed to elucidate the regulatory mechanisms of oestrogen
and antioestrogens on PTHrP secretion and production in
ER-positive breast cancer cells.
Up-regulation of PTHrP secretion by antioestrogens reminds us
that antioestrogens sometimes cause a flare phenomenon in
patients with advanced breast cancer (Plotkin et al, 1978; Coleman
et al, 1988). This unresolved phenomenon might be explained by
these data, i.e. a rapid increase in PTHrP secretion from breast
cancer cells may activate bone resorption by osteoclasts, which
may result in a transient increase in bone pain and may increase
the serum calcium level following a rise in the plasma PTHrP
level. It is well known that a rapid increase in bone pain and
temporary hypercalcaemia are common symptoms of the flare
phenomenon. This hypothesis should be clarified both in vitro and
in clinical studies.
The addition of 1 nM E2 clearly blocked the stimulation of
PTHrP secretion by both antioestrogens. These data suggest that
the regulation of PTHrP secretion may be mediated by ER.
Interestingly, an inhibitory effect ofcombined treatment with 1 nM
E2 and each antioestrogen on PTHrP secretion was similar to that
of treatment with 1 nM E2 alone. The binding affinity of ER for
oestrogen and antioestrogens in KPL-3C cells has not yet been
investigated. It might be possible that ER in KPL-3C cells is
mutated and its binding affinity or signal transduction pathway is
different from that of normal ER. Further analysis is needed to
clarify this phenomenon. On the other hand, a vitamin D analogue,
22-oxacalcitriol, was reported to act via vitamin D receptor and
inhibit the expression and secretion of PTHrP in some cell lines
(Inoue et al, 1993; Endo et al, 1994; Dvir et al, 1995). In addition,
a progestin, medroxyprogesterone acetate, dose-dependently
inhibited PTHrP secretion from the PgR-positive KPL-3C cell line
in our previous study (Kurebayashi et al, 1996). Our preliminary
study also suggested that oestrogen and antioestrogens did not
affect the PTHrP secretion from ER-negative MDA-MB 231
human breast cancer cells (data not shown). These findings
suggest that PTHrP secretion may be regulated via each steroid
hormone receptor. However, it has been reported that antioestro-
gens stimulate TGF-1 secretion from ER-positive breast cancer
cells (Knabbe et al, 1987) and thatTGF-0 stimulates PTHrP secre-
tion from a primary culture ofmammary epithelial cells and canine
squamous carcinoma cells (Ferrari et al, 1992; Merryman et al,
1994). It might be possible that antioestrogens stimulate TGF-3
secretion from KPL-3C cells and subsequently may increase
PTHrP secretion mediated by the TGF-3 receptor. The effects of
TGF-3 and its neutralizing antibody on PTHrP secretion from
KPL-3C cells are under investigation. Further studies are clearly
needed to clarify and elucidate this phenomenon.
As expected, oestrogen stimulated the cell cycle progression of
ER-positive KPL-3C cells and both antioestrogens caused a G -S
block on them. The effects of antioestrogens on the cell cycle
progression of ER-positive human breast cancer cells have been
extensively studied by many researchers (Sutherland et al, 1986).
Antioestrogens are well known to cause a G1-S block and subse-
quently result in a cytostatic effect on the cells. The experimental
results in this study support this phenomenon. Interestingly,
although both antioestrogens caused a cytostatic effect on KPL-3C
cells, they stimulated PTHrP secretion from the cells. In contrast, a
vitamin D analogue, oxacalcitriol, and medroxyprogesterone
acetate caused a cytostatic effect and inhibited PTHrP secretion in
this cell line (Kurebayashi et al, 1996; unpublished data). These
findings suggest that the regulation ofPTHrP secretion may not be
directly correlated with cell cycle progression. These interesting
phenomena should be further studied at the molecular level.
In conclusion, PTHrP secretion from ER-positive KPL-3C cells
was inhibited by oestrogen and stimulated by antioestrogens in
vitro. These data may explain a flare phenomenon caused by
antioestrogens in patients with breast cancer. Studies on the regu-
latory mechanisms of PTHrP secretion from breast cancer cells
may contribute to the development of new strategies not only for
the control of malignancy-associated hypercalcaemia but also for
the therapy ofbone metastasis.
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